Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II placebo-controlled trial of EDG-5506 in adults with Limb-girdle-muscular-dystrophy-type-2A, Duchenne-muscular-dystrophy and Glycogen-storage-disease-type-V

Next Previous
Trial Profile

A Phase II placebo-controlled trial of EDG-5506 in adults with Limb-girdle-muscular-dystrophy-type-2A, Duchenne-muscular-dystrophy and Glycogen-storage-disease-type-V

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevasemten (Primary)
  • Indications Duchenne muscular dystrophy; Glycogen storage disease type V; Limb girdle muscular dystrophy type 2A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DUNE
  • Sponsors Edgewise Therapeutics

Most Recent Events

  • 01 Oct 2024 According to an Edgewise Therapeutics media release, the study will be presented at the 29th International Annual Congress of the World Muscle Society (WMS). The conference will take place at The Prague Congress Centre in Prague, Czechia, October 8-12, 2024.
  • 22 Feb 2024 According to Edgewise Therapeutics Media Release, company expects to announce placebo-controlled data in the second quarter of 2024.
  • 09 Nov 2023 According to Edgewise Therapeutics Media Release, Company expects to announce placebo-controlled data in the first half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top